Is there a generic Steglujan? Your options compared

How to pay the least

Cash price

$520+ for 30 tablets

Pharmacies pay about this for Steglujan; you’d pay more.

Ask your pharmacy for Steglujan’s cash price, and one or two other pharmacies too.

Has to be Steglujan? With Optum Perks’ free coupon, Target (CVS) lists it for $586 for 30 tablets without insurance.

Get the free Optum Perks coupon

No generic is sold yet.

Compare every option

Brand nameSteglujan

Authorized genericertugliflozin and sitagliptin

Regular genericertugliflozin and sitagliptin

What you’d pay

At least$520for 30 tablets; pharmacies pay this

Not soldThere isn’t one

Not soldNone sold yet

Same as Steglujan?

The original

–

Brand nameWith a free discount coupon

Optum Perks, Optum’s free discount coupon, lists these prices for Steglujan without insurance. Show the coupon from its page at the pharmacy; it can’t be used with insurance.

Pick up in store: CVS Pharmacy $586for 30 tablets15/100 mg
Pick up in store: Walgreens $597for 30 tablets15/100 mg

From Optum Perks, read November 2, 2026, with no location set. Its page opens on this dose; other doses and pharmacies near you are priced there too. With insurance, check your co-pay first: it may be lower.

Authorized genericNot sold

There isn’t one. An authorized generic is Steglujan itself, from the same company, sold without the brand name, and usually for less. For now Steglujan is the only choice; ask the pharmacy for its cash price, or your plan what it charges.

See the brand name →

Regular genericNot sold

No generic is sold yet. Generics usually come once the brand’s patents and exclusivity end. Until then, ask the pharmacy for Steglujan’s cash price, or your plan what it charges.

See the brand name →

What it’s used for

Type 2 diabetes

What the FDA label says

STEGLUJAN is a combination of ertugliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, and sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Limitations of Use:

Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus.
Has not been studied in patients with a history of pancreatitis.

Source: the FDA label for Steglujan (Merck Sharp & Dohme LLC), June 3, 2026. Full label on DailyMed

Good to know

We didn’t find a savings card from Steglujan’s maker.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.

Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/steglujan/